Organon – Paid Day Off on International Women’s Day

Barbara J. Stegmann, Clinical Lead, Women’s Health at Organon and OB/GYN, discusses the company’s efforts to recognize the growing women’s health inequities exacerbated by the pandemic, including Organon’s decision to declare International Women’s Day (IWD) a paid day off for its employees to focus on their own health. She addresses the major inequities plaguing women’s health today and how healthcare providers can help to close these gaps and ensure women are prioritizing their health.

Dr. Barbara Stegmann is the clinical lead for women’s health at Organon, a company whose vision is to advance the health of women. In her role, she works to bring new medicines and other solutions through clinical development and to the market to address women’s unmet medical needs. Barbara comes to Organon with significant healthcare experience, as a clinician, researcher and as a doctor. Previously, she was the director of women’s health clinical research at Merck, where she spearheaded the NDA filing for Elonva in the U.S. She also served as a medical director for Aspire Fertility Centers. Earlier in her career, she worked for NASA, focusing on the health of astronauts in the program. Barbara received a medical degree from the University of Missouri-Kansas City and completed her fellowship at the National Institutes of Health. She holds a master of public health in epidemiology from the University of North Carolina and a PhD in epidemiology from the University of Iowa. She is triple board certified in reproductive endocrinology and infertility, OB/GYN and aerospace medicine. Barbara has authored more than 40 scientific publications and served as a reviewer for significant medical journals such as Fertility and Sterility and the New England Journal of Medicine. She is a fellow with the American College of OB/GYN and a member of the American Society for Reproductive Medicine and the Society of Reproductive Endocrinology and Infertility.